Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -31.37% is in line with its 5-year average of -30.14%, around the middle of its 5-year range (-53.88%–5.54%).
35.89% above its 12-month average of -48.93%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.02%.
RETURN ON ASSETS (ROA)
-31.37%
RETURN ON ASSETS (ROA) AVG TTM
-48.93%
RETURN ON ASSETS (ROA) AVG 3Y
-40.51%
RETURN ON ASSETS (ROA) AVG 5Y
-30.14%
RETURN ON ASSETS (ROA) AVG 10Y
-42.63%
RETURN ON ASSETS (ROA) AVG 15Y
-54.36%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+35.89%
CURRENT VS 3Y AVG
+22.57%
CURRENT VS 5Y AVG
-4.09%
CURRENT VS 10Y AVG
+26.42%
CURRENT VS 15Y AVG
+42.30%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+2.77%
vs the sector median at left
Syndax Pharmaceuticals, Inc.
Market Cap
$1.54B
Return on Assets (ROA)
-31.37%
TTM Avg
-48.93%
3Y Avg
-40.51%
5Y Avg
-30.14%
Market Cap
$1.54B
Return on Assets (ROA)
20.98%
TTM Avg
9.19%
3Y Avg
12.55%
5Y Avg
16.89%
Market Cap
$1.57B
Return on Assets (ROA)
-52.77%
TTM Avg
-17.21%
3Y Avg
-29.94%
5Y Avg
-28.87%
Market Cap
$1.50B
Return on Assets (ROA)
18.65%
TTM Avg
7.83%
3Y Avg
-23.56%
5Y Avg
-4.38%
Market Cap
$1.50B
Return on Assets (ROA)
10.96%
TTM Avg
-5.00%
3Y Avg
-12.25%
5Y Avg
-27.07%
Market Cap
$1.59B
Return on Assets (ROA)
-43.15%
TTM Avg
-37.60%
3Y Avg
-124.49%
5Y Avg
-99.59%
Market Cap
$1.49B
Return on Assets (ROA)
-29.88%
TTM Avg
-23.31%
3Y Avg
-25.68%
5Y Avg
-25.68%
Market Cap
$1.48B
Return on Assets (ROA)
6.64%
TTM Avg
5.09%
3Y Avg
3.45%
5Y Avg
4.26%
Market Cap
$1.60B
Return on Assets (ROA)
-25.60%
TTM Avg
-33.58%
3Y Avg
-30.56%
5Y Avg
-19.71%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Syndax Pharmaceuticals, Inc. (SNDX) | $1.54B | -31.37% | -48.93% | -40.51% | -30.14% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 20.98% | 9.19% | 12.55% | 16.89% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.57B | -52.77% | -17.21% | -29.94% | -28.87% |
| Nutex Health, Inc. (NUTX)vs › | $1.50B | 18.65% | 7.83% | -23.56% | -4.38% |
| Eton Pharmaceuticals, Inc. (ETON)vs › | $1.50B | 10.96% | -5.00% | -12.25% | -27.07% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.59B | -43.15% | -37.60% | -124.49% | -99.59% |
| Rapport Therapeutics, Inc. Common Stock (RAPP)vs › | $1.49B | -29.88% | -23.31% | -25.68% | -25.68% |
| Phibro Animal Health Corporation (PAHC)vs › | $1.48B | 6.64% | 5.09% | 3.45% | 4.26% |
| uniQure N.V. (QURE)vs › | $1.60B | -25.60% | -33.58% | -30.56% | -19.71% |
| GH Research PLC (GHRS)vs › | $1.48B | -16.72% | -18.71% | -15.50% | -12.14% |
ROA
-31.4%
ROE
-1462.1%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -53.88% |
| 2024-12-31 | -43.98% |
| 2023-12-31 | -34.16% |
| 2022-12-31 | -30.03% |
| 2021-12-31 | 5.54% |
| 2020-12-31 | -24.31% |
| 2019-12-31 | -88.08% |
| 2018-12-31 | -88.11% |
| 2017-12-31 | -44.32% |
| 2016-12-31 | -40.80% |
| 2015-12-31 | -26.83% |
| 2014-12-31 | -154.71% |
| 2013-12-31 | -83.06% |
| 2012-12-31 | -659.93% |
| 2011-12-31 | -273.49% |
